Mitochondrial Encephalopathy Lactic Acidosis and Stroke-Like Episodes (MELAS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Mitochondrial Encephalopathy Lactic Acidosis and Stroke-Like Episodes (MELAS) is a rare neurometabolic genetic disorder that is progressive and multisystemic due to mitochondrial dysfunction and that is characterized by encephalomyopathy, lactic acidosis, and stroke-like episodes. MELAS can result from mutations in one of several genes, including MT-ND1, MT-ND5, MT-TH, MT-TL1, and MT-TV. These genes are found in the DNA of cellular structures called mitochondria, which convert the energy from food into a form that cells can use.
·
Estimated MELAS prevalence has been reported
at about 0.2/100,000 in Japan. It is one of the most frequent mitochondrial
disorders, estimated to affect 1/10,000 people.
Thelansis’s “Mitochondrial
Encephalopathy Lactic Acidosis and Stroke-Like Episodes (MELAS) Market Outlook,
Epidemiology,
Competitive Landscape, and Market Forecast Report – 2021 To
2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Mitochondrial Encephalopathy Lactic
Acidosis and Stroke-Like Episodes (MELAS) treatment modalities options for
eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Mitochondrial Encephalopathy Lactic Acidosis and Stroke-Like Episodes
(MELAS) across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Mitochondrial Encephalopathy Lactic
Acidosis and Stroke-Like Episodes (MELAS) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking and
proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment